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Expression profiling of tumours from cancer patients has uncovered several genes that are critically important in the progression of a
normal cell to an oncogenic phenotype. Leading the way in these discoveries is the use of microarrays, a technology that is currently
in transition from basic science applications to use in the clinic. Microarrays can determine the global gene regulation of an individual
cancer, which may be useful in formulating an individualised therapy for the patient. Currently, cells used in breast cancer microarray
studies often come from either homogenous cultures or heterogeneous biopsy samples. Both cell sources are at a disadvantage in
determining the most accurate gene profile of cancer, which often consists of multiple subspecies of cancerous cells within a
background of normal cells. Therefore, acquisition of small, but highly specific biopsies for analysis may be required for an accurate
expression analysis of the disease. Amplification methods, such as polymerase chain reaction (PCR) and amplified antisense RNA
(aRNA) amplification, have been used to amplify the mRNA signal from very small samples, which can then be used for microarray
analysis. In this study, we describe the acquisition, amplification, and analysis of very small samples (o10000 cells) for expression
analysis and demonstrate that the ultimate resolution of cancer expression analysis, one cell, is both feasible and practical.
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Many human diseases are intricately linked to aberrant changes in
gene expression. Cells with arguably the most profound genetic
reprogramming are found in cancer, a disease that accounts for
nearly one-quarter of all deaths in the United States (2003).
Fortunately, advances in cancer drug development and other
therapeutics have reduced mortality rates in several types of cancer.
While the mortality rates for several types of cancer have been
reduced, little change has been seen in the mortality rate of breast
cancer, a statistic that is complicated by the fact that even though
improved therapies have been developed, an everincreasing
caseload is being generated from an increased lifespan. In response
to these high mortality rates, public and private funding entities
have made breast cancer research a high priority, which has
accelerated the use of newly developed diagnostic technologies for
early detection to be used in the breast cancer. As an example of
how small sample mRNA analysis may help in the evaluation and
treatment of cancer, we will concentrate our discussion upon
breast cancer, for which there has been significant molecular
analysis over the last decade.
BREAST CANCER
One of the striking aspects of breast cancer is the variability in its
phenotypic manifestation across different patients (Murphy et al,
1995). Doubling rates of growth of breast cancer tumours in
patients can range from 2 weeks to 5 years. The progression of
these tumours into metastatic disease is unpredictable as well,
attesting to the heterogeneity of breast cancer from patient to
patient. Although breast cancers can be classified by several
indices including tumour size, metastasis, etc., the current
standard for determining treatment of metastatic breast cancer is
lymph node involvement and the expression of three specific
genes: the oestrogen receptor, the progesterone receptor and the
HER-2/neu oncogene (Bast et al, 2001). The identification of
these genes as important markers for breast cancer is the result
of many years of classical expression profiling, where only a
few genes could be monitored at one time. These methods have
also uncovered several other genes (CAE, Ki-67, Ca 15-3, Ca 27, Ca
29, cathespin) that may eventually be used in breast cancer
diagnosis and treatment (Bast et al, 2001). However, to uncover the
totality of genes that contribute to the breast cancer phenotype,
future directions will require a genome-wide approach where all
genes in a cancer can be assayed simultaneously. Total gene
surveillance can be accomplished by the use of microarrays.
MICROARRAY TECHNOLOGY
Microarray-based expression profile technology is based on
hybridisation methods first employed nearly 30 years ago (South-
ern et al, 1999). RNA from cells are reverse transcribed into
cDNAs, which are then fluorescently or radioactively labelled and
used to probe a predetermined set of DNAs. The greater the
hybridisation signal from probe-DNA binding, the higher the
concentration of the RNA within the original sample. Currently,
upwards of 35000 genes can be analysed at one time on a
microarray.
Initial expression profiling efforts used large amounts of cells
(410
6 cells), often harvested from large tumours or cell lines
(Forozan et al, 2000). Although cancers arise from a single cellular
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heterogeneity within the cell mass (Wild et al, 2000). Cells isolated
from the periphery of the tumour can have mRNA expression
patterns distinct from cells located deep within the tumour. Cells
that metastasise elsewhere in the body can acquire several
genotypical and phenotypical differences from those of the
primary cancer, which may allow these cells to react differently
to therapy than those at the primary site (Nishizuka et al, 2002).
Therefore, harvesting of and analysis of gross quantities of tumour
for expression analysis may not give an accurate assessment of the
cancer needed for determining which therapeutic intervention to
use.
The large amount of RNA needed for microarray analysis (2–
10mg) can also be problematic. For instance, the use of
mammography and early detection campaigns has resulted in
early detection of smaller tumours that can be sampled for
expression analysis. Fine-needle aspiration (FNA), a method for
obtaining small amounts of tumour cells (o100000) for histolo-
gical identification of cancer has become the standard for tumour
sampling (Krawczyk et al, 2000). However, the amount of RNA
that can be harvested from a FNA biopsy (B2mg) is at the lower
limit for use in microarray studies without the use of amplification
methods (Assersohn et al, 2002; Symmans et al, 2003). Fine-needle
aspiration samples also contain a high percentage of noncancerous
cells (20–60%), making a true representation of a cancer
expression profile difficult (Assersohn et al, 2002; Symmans et al,
2003).
Cancer-specific cellular samples for microarray analysis can be
obtained through microdissection of tumour sections (Wild et al,
2000; Zhu et al, 2003). Cells obtained from biopsies can be
mounted and isolated using laser capture microdissection (LCM),
then placed into a microcentrifuge tube for cDNA synthesis.
Samples containing as few as 1–10 cells can be isolated in this
manner, and subsequently used in microarray experiments
(Kamme et al, 2003; Seshi et al, 2003). Alternatively, similar
samples can also be obtained through manual microdissection,
where single-cell isolation can be accomplished using microma-
nipulators and pulled glass micropipettes as scalpels (Eberwine
et al, 1992; O’Dell et al, 1998). Once separated from the cell matrix,
the cell body is aspirated into the micropipette and placed into a
sample tube for analysis. It is important to note that prior to
dissection with this procedure, the mRNA is converted into cDNA
using an oligonucleotide primer (Tecott et al, 1988). This is one
distinction between LCM isolated mRNAs that are generally
nonfixed and the manual microdissection of fixed tissues. The
harvesting of a single cell from a fixed tissue section is shown in
Figure 1. This method should be quite effective in the isolation of
pure cancer cell samples from FNAs. Fine-needle aspiration
samples can be plated and fixed onto glass coverslips. After
immunostaining, individual positive-stained cells can easily be
aspirated. Single-cell dissection can be further optimised by using
a microchisel. The vibrating blade allows efficient cutting of the
cell body from the cell matrix without disrupting neighbouring
cells. The microchisel can also be used in the dissection of
highly elastic nonfixed tissue, raising the possibility of using
live cells for expression profiling. Live cells may be more attractive
for expression profiling of small samples, as the mRNA is not
affected by fixatives that can crosslink the RNA to proteins
and other molecules, resulting in lower RNA yields (author’s
observation). This procedure on live cells has permitted sub-
regions of live cells to be harvested and assayed for mRNA
abundances using macroarrays (Miyashiro et al, 1994; Crino and
Eberwine, 1996).
mRNA AMPLIFICATION
As it becomes necessary to sample smaller amounts of cells for
microarray analysis, it becomes clear that an amplification of the
cDNA signal is needed. Polymerase chain reaction, a powerful
exponential amplification procedure, can be used for quantitative
gene-specific amplification of individual cDNAs (Stirling,
2003). However, PCR is limited in its ability to globally amplify
the entire transcriptome of a cell, as PCR amplifies long, GC-rich
sequences with less efficiency than short, AT-rich sequences,
resulting in skewed amplification levels from gene to gene that are
carried over into each successive (430) round (Polz and
Cavanaugh, 1998). Owing to of these limitations, most microarray
amplification methods make use of a linear-based amplification
method using T7 RNA polymerase, resulting in an amplified RNA
(aRNA) (Figure 2) (Van Gelder et al, 1990). In this strategy, polyA
RNA is primed for cDNA synthesis by a polyT oligonucleotide
containing the 17bp sequence for the T7 RNA polymerase
promoter. After second-strand synthesis is completed, the
template is then transcribed by a highly concentrated T7
polymerase, resulting in a B2000-fold amplification of antisense
RNA that can be used for hybridisation analysis (Phillips and
Eberwine, 1996).
Currently, most microarray studies that utilise the aRNA
synthesis protocol require one amplification round, allowing as
little as 10ng or 1000 cells to be used for the initial input
(Sotiriou et al, 2002; Yunes et al, 2003). However, smaller
amounts of cellular material require a second round of amplifica-
tion. A second (and any subsequent) round requires the use of
random primers in reverse transcribing the output aRNA from
the preceding round. The polyT-T7 oligonucleotide is then
used to prime second-strand synthesis. The resulting template is
again transcribed by T7 RNA polymerase, creating a second
amplification of aRNA. As each round of aRNA synthesis can
amplify the template 2000-fold, a second round will result in a
410
6-fold amplification. At this level of amplification, the
transcriptome of a single cell can be analysed (Eberwine et al,
Figure 1 mRNA harvesting for single cells. These panels show the progression for harvesting of RNA from a single cell in a fixed tissue section. Initially, in
situ transcription is performed on the tissue with the amplification primer followed by immunohistochemistry to identify cells expressing a particular antigen.
The immunopositive cells are imaged under a microscope (A) and a patch pipette is apposed to an individual cell (B) and the material aspirated into the
pipette (C) leaving a hole where the cell was removed (D). The cDNA is removed from the isolated tissue and processed through the aRNA amplification
procedure. These photos were taken by Paolo Marciano for studies detailing changes in gene expression associated with apoptosis.
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cycles of aRNA amplification have been successfully performed
and the products are used as probes on microarrays (Xiang et al,
2003). The only limitation for extra rounds of amplification arises
from the use of random primers, which results in a 30% shortening
of the transcript after each round (personal observation). There-
fore, the aRNA method will have a 30 bias. This bias will have
only a slight effect on the hybridisation of cDNA-based arrays
that utilize the entire gene sequence. Oligonucleotide-based
microarrays are often designed using 30 sequences of genes,
and therefore may not be affected by this 30-end bias (Luzzi et al,
2003). This 30-end bias may be eliminated through the use of
random dodecamer-T7 oligonucleotide primers that will prime
cDNA synthesis along the length of the mRNA, not simply at the
30-end. This comes at the price of generating smaller cDNAs and
having a large amount of ribosomal RNA amplified as part of the
probe.
USE OF SINGLE-CELL PROFILING IN
BREAST CANCER
The heterogeneity and unpredictable behaviour of breast cancer
strongly encourage a closer look into the cast of ‘cellular
characters’ that are responsible for the invasive and proliferative
nature of this disease. Single-cell profiling would be helpful in
characterising cells that have specific roles in the cancerous
phenotype.
Invasive tumour cells can release factors that allow them
to pass through several layers of epithelium (Nozaki et al,
2000). Since cancer cells that border normal tissue are in a
great minority to those cells within the tumour mass, whole
tumour expression profiling would not easily allow the
identification of genes associated with this invasive cell subtype.
Indeed, differences in gene expression have been seen within
different areas of breast cancer carcinomas (Zhu et al, 2003).
The identification of new gene markers at the tumour interface
through single-cell profiling could allow for a more precise
measurement of the invasiveness of the tumour, and may one
day help in the decision-making process for effective therapeutic
action.
In a similar fashion, tumour cells that border sites of
angiogenesis may express genes that promote the formation of
blood vessels to the tumour. Through single-cell profiling, specific
genes that are found differentially regulated in these cells relative
to noncancerous host cells may be used as drug targets for
combating cancer-induced angiogenesis.
Probably one of the most powerful aspects of single-cell
profiling would be the tracking of a cancer at the cellular
level as the patient undergoes treatment. Active cancers often
release millions of living cells into the bloodstream daily, where
they can be identified in a blood sample though fluorescence-
activated cell sorting or plating procedures, then analysed
for mRNA expression (Kim et al, 2003; Weigelt et al, 2003;
Zabaglo et al, 2003). As the patient goes through days or weeks
of treatment, expression profiles from individual cancer cells
isolated from blood would give an indication of which particular
subtype of cancer cell is most prevalent in the body. Data from
these experiments could prove powerful in determining the
mechanisms of selection of a resistant tumour subtype for a
particular therapy, and may be beneficial in developing therapeutic
strategies based upon the expression profile of the initial
circulating cells.
Finally, a major advantage of using a multigenic approach to
the analysis of cancer-associated gene expression in single cells is
that the alteration of abundances of multiple mRNAs suggests
that the protein levels for the corresponding mRNAs may likewise
be altered. Further, there is the implication that if mRNA
abundances are altered, then the abundance of corresponding
functional proteins may also be altered. While this is not
necessarily the case, it is reasonable to follow up microarray data
by determining protein abundances (Zhang et al, 2001) and
protein functional data. In this manner, insight into combinations
of proteins that are altered as a result of cancer may be
determined. This information may permit the identification of
multiple drugs that act on different proteins, which when used in
combination may prove to be an effective cancer therapeutic. Such
combinatorial therapies that selectively impact a cancerous cell
would be difficult to develop without single-cell gene and protein
expression data.
CONCLUSION
The increased longevity of the Western population has come
with the price of increasing numbers of cancer cases. As we
try to develop better chemotherapeutics for combating this
disease, we must first elucidate the mechanisms that contribute
to the phenotype. Given the heterogeneity of inter- and
intracellular phenotypes associated with any cancer, it is reason-
able to suggest that cancer may be understood as the sum of
its parts. By identifying the minute differences in mRNA and
protein abundances between cancer cell subtypes in patients, we
may develop combinatorial therapeutics that will combat the




























Figure 2 First and second rounds of the aRNA procedure. (A) mRNA is
reverse transcribed using polyT-T7 primer. (B) Second-strand synthesis
primed by hair-pining or random primers. (C) T7 RNA polymerase-
mediated transcription, creating amplified antisense RNA. (D) Reverse
transcription of antisense RNA using random hexamers. (E) Second-strand
synthesis using polyT-T7 primer. (F) T7 RNA polymerase-mediated
transcription, again creating antisense RNA. Further rounds of amplification
are performed by repeated steps (D) through (F).
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